Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice

Hypertension

Volumn 72, Issue 1, 2018, Pages 24-43

  Brown, Mark A ^a   Magee, Laura A ^b   Kenny, Louise C ^c,d   Karumanchi, S Ananth ^e   McCarthy, Fergus P ^d   Saito, Shigeru ^f   Hall, David R ^g   Warren, Charlotte E ^h   Adoyi, Gloria ⁱ   Ishaku, Salisu ⁱ  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Irish Centre for Fetal and Neonatal Translational Research   (Ireland)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TOYAMA   (Japan)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h POPULATION COUNCIL   (United States)

ⁱ Population Council Nigeria   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ESSENTIAL HYPERTENSION; FEMALE; FETUS MONITORING; HUMAN; HYPERTENSION; INTRAPARTUM CARE; KIDNEY DISEASE; MASKED HYPERTENSION; MATERNAL HYPERTENSION; POSTNATAL CARE; PRACTICE GUIDELINE; PREDICTION; PREECLAMPSIA; PRENATAL CARE; PRIORITY JOURNAL; PROTEINURIA; PUERPERIUM; REVIEW; VITAMIN SUPPLEMENTATION; WHITE COAT HYPERTENSION; BLOOD PRESSURE MONITORING; CLASSIFICATION; DISEASE MANAGEMENT; PREGNANCY; PROCEDURES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY;

EID: 85053806850     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.10803     Document Type: Review

References (116)

1. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: A systematic review of International Clinical Practice Guidelines. PLoS One. 2014;9:e113715. doi: 10.1371/journal. pone.0113715.
2. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97-104. doi: 10.1016/j.preghy.2014.02.001.
3. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2013;3:44-47. doi: 10.1016/j.preghy. 2012.11.001.
4. Redman CWG, Jacobson S-L, Russell R. Hypertension in pregnancy. In: Powrie R, Greene M, Camann W, eds. de Swiet's Medical Disorders in Obstetric Practice. 5th ed. Oxford, UK: Blackwell Publishing; 2010:153-181.
5. Lee-Ann Hawkins T, Brown MA, Mangos GJ, Davis GK. Transient gestational hypertension: not always a benign event. Pregnancy Hypertens. 2012;2:22-27. doi: 10.1016/j.preghy.2011.09.001.
6. Davis GK, Roberts LM, Mangos GJ, Brown MA. Comparisons of auscultatory hybrid and automated sphygmomanometers with mercury sphygmomanometry in hypertensive and normotensive pregnant women: parallel validation studies. J Hypertens. 2015;33:499-505. doi: 10.1097/HJH.0000000000000420.
7. Waugh JJ, Gupta M, Rushbrook J, Halligan A, Shennan AH. Hidden errors of aneroid sphygmomanometers. Blood Press Monit. 2002;7:309-312. doi: 10.1097/01.mbp.0000047141.34024.06.
8. Brown MA, Roberts L, Davis G, Mangos G. Can we use the Omron T9P automated blood pressure monitor in pregnancy? Hypertens Pregnancy. 2011;30:188-193. doi: 10.3109/10641955.2010.507854.
9. dabl Educational Trust. Blood Pressure Monitors-Validations, Papers and Reviews. Recommended Devices by Manufacturer. http://www. dableducational.org/sphygmomanometers/recommended-brand.html. Accessed April 30, 2018.
10. Nouwen E, Snijder M, van Montfrans G, Wolf H. Validation of the Omron M7 and Microlife 3BTO-A blood pressure measuring devices in preeclampsia. Hypertens Pregnancy. 2012;31:131-139. doi: 10.3109/ 10641955.2010.544799.
11. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol. 2010;115(2 pt 1):365-375. doi: 10.1097/AOG.0b013e3181cb9644.
12. Côté AM, Firoz T, Mattman A, Lam EM, von Dadelszen P, Magee LA. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol. 2008;199:625.e1-625.e6. doi: 10.1016/j.ajog.2008.06.009.
13. Côté AM, Brown MA, Lam E, von Dadelszen P, Firoz T, Liston RM, Magee LA. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ. 2008;336:1003-1006. doi: 10.1136/bmj.39532.543947.BE.
14. Saudan PJ, Brown MA, Farrell T, Shaw L. Improved methods of assessing proteinuria in hypertensive pregnancy. Br J Obstet Gynaecol. 1997;104:1159-1164.
15. Cade TJ, Gilbert SA, Polyakov A, Hotchin A. The accuracy of spot urinary protein-to-creatinine ratio in confirming proteinuria in pre-eclampsia. Aust N Z J Obstet Gynaecol. 2012;52:179-182. doi: 10.1111/j.1479-828X. 2011.01409.x.
16. Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ. 2012;345:e4342.
17. Phelan LK, Brown MA, Davis GK, Mangos G. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. Hypertens Pregnancy. 2004;23:135-142. doi: 10.1081/PRG-120028289.
18. Brown MA. Pre-eclampsia: proteinuria in pre-eclampsia-does it matter any more? Nat Rev Nephrol. 2012;8:563-565. doi: 10.1038/nrneph.2012.190.
19. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric preeclampsia: A novel risk indicator in women with gestational hypertension. J Hypertens. 2008;26:295-302. doi: 10.1097/HJH.0b013e3282f1a953.
20. Payne B, Magee LA, Côté AM, et al; PIERS Study Group (Appendix). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33:588-597. doi: 10.1016/ S1701-2163(16)34907-6.
21. Chan P, Brown M, Simpson JM, Davis G. Proteinuria in pre-eclampsia: how much matters? BJOG. 2005;112:280-285. doi: 10.1111/j.1471-0528. 2004.00395.x.
22. Mateus J, Newman R, Sibai BM, Li Q, Barton JR, Combs CA, Guzman E, Boggess KA, Gyamfi C, von Dadelszen P, Woelkers D. Massive urinary protein excretion associated with greater neonatal risk in preeclampsia. AJP Rep. 2017;7:e49-e58. doi: 10.1055/s-0037-1601866.
23. Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol. 2009;200:392.e1-392.10. doi: 10.1016/j.ajog.2008.10.033.
24. Brown MA, Mangos G, Davis G, Homer C. The natural history of white coat hypertension during pregnancy. BJOG. 2005;112:601-606. doi: 10.1111/j.1471-0528.2004.00516.x.
25. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:1263-1269.
26. Brown MA, Robinson A, Bowyer L, Buddle ML, Martin A, Hargood JL, Cario GM. Ambulatory blood pressure monitoring in pregnancy: what is normal? Am J Obstet Gynecol. 1998;178:836-842.
27. Tremonti C, Beddoe J, Brown MA. Reliability of home blood pressure monitoring devices in pregnancy. Pregnancy Hypertens. 2017;8:9-14. doi: 10.1016/j.preghy.2017.01.002.
28. Livingston JR, Payne B, Brown MA, Roberts JM, Côté AM, Magee LA, von Dadelszen P, PIERS Study Group. Uric acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36:870-877. doi: 10.1016/S1701-2163(15)30435-7.
29. Hawkins TL, Roberts JM, Mangos GJ, Davis GK, Roberts LM, Brown MA. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: A retrospective cohort study. BJOG. 2012;119:484-492. doi: 10.1111/j.1471-0528.2011.03232.x.
30. Martin AC, Brown MA. Could uric acid have a pathogenic role in preeclampsia? Nat Rev Nephrol. 2010;6:744-748. doi: 10.1038/nrneph. 2010.125.
31. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol. 1998;105:1177-1184.
32. Davis GK, Mackenzie C, Brown MA, Homer CS, Holt J, McHugh L, Mangos G. Predicting transformation from gestational hypertension to preeclampsia in clinical practice: A possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy. 2007;26:77-87. doi: 10.1080/10641950601147952.
33. Theilen LH, Fraser A, Hollingshaus MS, Schliep KC, Varner MW, Smith KR, Esplin MS. All-cause and cause-specific mortality after hypertensive disease of pregnancy. Obstet Gynecol. 2016;128:238-244. doi: 10.1097/AOG.0000000000001534.
34. Wikström AK, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112:1486-1491. doi: 10.1111/j.1471-0528.2005.00733.x.
35. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326:845. doi: 10.1136/bmj.326.7394.845.
36. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53:944-951. doi: 10.1161/HYPERTENSIONAHA.109.130765.
37. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:2400. doi: 10.1056/NEJMc1713798.
38. Bartsch E, Medcalf KE, Park AL, Ray JG; High Risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. doi: 10.1136/bmj.i1753.
39. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056/NEJMoa031884.
40. Baweja S, Kent A, Masterson R, Roberts S, McMahon LP. Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography. BJOG. 2011;118:1126-1132. doi: 10.1111/j.1471-0528.2011.02960.x.
41. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis. BJOG. 2012;119:778-787. doi: 10.1111/j.1471-0528.2012.03311.x.
42. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, Montico M, D'Ottavio G. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta. 2012;33:495-501. doi: 10.1016/j.placenta.2012.03.003.
43. Myatt L, Clifton RG, Roberts JM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119:1234-1242. doi: 10.1097/AOG.0b013e3182571669.
44. Masoura S, Kalogiannidis IA, Gitas G, Goutsioulis A, Koiou E, Athanasiadis A, Vavatsi N. Biomarkers in pre-eclampsia: A novel approach to early detection of the disease. J Obstet Gynaecol. 2012;32:609-616. doi: 10.3109/01443615.2012.709290.
45. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.
46. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, Quezada S. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during the first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013:41:538-544. doi: 10.1002/uog.12264.
47. Kho EM, McCowan LM, North RA, Roberts CT, Chan E, Black MA, Taylor RS, Dekker GA; SCOPE Consortium. Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol. 2009;82:66-73. doi: 10.1016/j.jri.2009.04.011.
48. Verwoerd GR, Hall DR, Grové D, Maritz JS, Odendaal HJ. Primipaternity and duration of exposure to sperm antigens as risk factors for pre-eclampsia. Int J Gynaecol Obstet. 2002;78:121-126.
49. Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD, Sibai BM. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 2003;157:1108-1114.
50. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 2002;346:33-38. doi: 10.1056/NEJMoa011379.
51. Lykke JA, Bare LA, Olsen J, Lagier R, Arellano AR, Tong C, Paidas MJ, Langhoff-Roos J. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost. 2012;10:1320-1325. doi: 10.1111/j.1538-7836.2012.04773.x.
52. Al-Rubaie Z, Askie LM, Ray JG, Hudson HM, Lord SJ. The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: A systematic review. BJOG. 2016;123:1441-1452. doi: 10.1111/1471-0528.14029.
53. O'Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49:756-760. doi: 10.1002/uog.17455.
54. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13-22. doi: 10.1056/NEJMoa1414838.
55. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study. Circulation. 2013;128:2121-2131. doi: 10.1161/CIRCULATIONAHA.113.003215.
56. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-919. doi: 10.1161/CIRCULATIONAHA. 111.054361.
57. von Dadelszen P, Payne B, Li J, et al; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377:219-227. doi: 10.1016/S0140-6736(10)61351-7.
58. Payne B, Hodgson S, Hutcheon JA, Joseph KS, Li J, Lee T, Magee LA, Qu Z, von Dadelszen P; PIERS Study Group. Performance of the full-PIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120:113-118. doi: 10.1111/j.1471-0528.2012.03496.x.
59. Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, Ganzevoort W, Akkermans J, Kerry S, Mol BW, Moons KG, Riley RD, Khan KS; PREP Collaborative Network. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC Med. 2017;15:68. doi: 10.1186/s12916-017-0827-3.
60. Berghella V, Saccone G. Exercise in pregnancy! Am J Obstet Gynecol. 2017;216:335-337. doi: 10.1016/j.ajog.2017.01.023.
61. Di Mascio D, Magro-Malosso ER, Saccone G, Marhefka GD, Berghella V. Exercise during pregnancy in normal-weight women and risk of preterm birth: A systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2016;215:561-571. doi: 10.1016/j.ajog.2016.06.014.
62. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007. Art No CD004659.
63. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010. Art No CD001059.
64. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol. 2010;116(2 pt 1):402-414. doi: 10.1097/AOG.0b013e3181e9322a.
65. Lane C, Pirabhahar S, Robins J, Tranter S, Brown M, Katz I. Improving nephrology service delivery: accessing the specialist. Aust Fam Physician. 2016;45:223-228.
66. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks'; gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216:121.e2-128.e2. doi: 10.1016/j.ajog.2016.10.016.
67. Tong S, Mol BW, Walker SP. Preventing preeclampsia with aspirin: does dose or timing matter? Am J Obstet Gynecol. 2017;216:95-97. doi: 10.1016/j.ajog.2016.12.003.
68. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:110.e6-120.e6. doi: 10.1016/j.ajog.2016.09.076.
69. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks'; gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216:121.e2-128.e2.
70. Groom K, McCowan L, MacKay L, Said J, Kane S, Walker S, Middeldorp S, Stone P, McLintock C. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history (the eppi trial): an open-label international multicentre randomized controlled trial. Am J Obstet Gynecol. 2017;216(suppl 1):S4.
71. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, DerSimonian R, Esterlitz JR, Raymond EG, Bild DE, Clemens JD, Cutler JA. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69-76 doi: 10.1056/NEJM199707103370201.
72. Barakat R, Pelaez M, Cordero Y, Perales M, Lopez C, Coteron J, Mottola MF. Exercise during pregnancy protects against hypertension and macrosomia: randomized clinical trial. Am J Obstet Gynecol. 2016;214:649. e1-649.e8. doi: 10.1016/j.ajog.2015.11.039.
73. Rumbold A DL, Crowther CA, Haslam RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev. 2008. Art No CD004227.
74. Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, diagnosis, and management of intrauterine growth restriction. J Obstet Gynaecol Can. 2012;34:17-28. doi: 10.1016/S1701-2163(16)35129-5.
75. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, Poston L, Roberts JM; Global Pregnancy CoLaboratory. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63:1293-1301. doi: 10.1161/HYPERTENSIONAHA.113.02664.
76. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: A randomised controlled trial. BJOG. 2000;107:759-765.
77. Harper LM, Biggio JR, Anderson S, Tita AT. Gestational age of delivery in pregnancies complicated by chronic hypertension. Obstet Gynecol. 2016;127:1101-1109. doi: 10.1097/AOG.0000000000001435.
78. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407-417. doi: 10.1056/NEJMoa1404595.
79. Bramham K, Hladunewich MA, Jim B, Maynard SE. Pregnancy and Kidney disease. NephSAP. 2016;15:109-229.
80. Alkhunaizi A, Melamed N, Hladunewich MA. Pregnancy in advanced chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2015;24:252-259. doi: 10.1097/MNH.0000000000000119.
81. Piccoli GB, Attini R, Vasario E, Conijn A, Biolcati M, D'Amico F, Consiglio V, Bontempo S, Todros T. Pregnancy and chronic kidney disease: A challenge in all CKD stages. Clin J Am Soc Nephrol. 2010;5:844-855. doi: 10.2215/CJN.07911109.
82. Hladunewich MA, Hou S, Odutayo A, Cornelis T, Pierratos A, Goldstein M, Tennankore K, Keunen J, Hui D, Chan CT. Intensive hemodialysis associates with improved pregnancy outcomes: A Canadian and United States cohort comparison. J Am Soc Nephrol. 2014;25:1103-1109. doi: 10.1681/ASN.2013080825.
83. Brown MA. Is there a role for ambulatory blood pressure monitoring in pregnancy? Clin Exp Pharmacol Physiol. 2014;41:16-21. doi: 10.1111/1440-1681.12106.
84. Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension? Am J Obstet Gynecol. 2012;207:214.e1-214.e6. doi: 10.1016/j.ajog.2012.06.009.
85. Kenneth L, Hall DR, Gebhardt S, Grové D. Late onset preeclampsia is not an innocuous condition. Hypertens Pregnancy. 2010;29:262-270. doi: 10.3109/10641950902777697.
86. Magee LA, von Dadelszen P, Singer J, et al; CHIPS Study Group. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood pressure? Hypertension. 2016;68:1153-1159. doi: 10.1161/HYPERTENSIONAHA. 116.07862.
87. Magee LA, Helewa M, Rey E; Hypertension Guideline Committee; Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(suppl 3):S1-S2. doi: 10.1016/S1701-2163(16)32776-1.
88. National Institute for Health and Clinical Excellence: Guidance. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London, UK: RCOG Press; 2010.
89. SMFM Publications Committee. SMFM Statement: benefit of antihypertensive therapy for mild-to-moderate chronic hypertension during pregnancy remains uncertain. Am J Obstet Gynecol. 2015;213:3-4. doi: 10.1016/j.ajog.2015.04.013.
90. Easterling TR. Post-Control of Hypertension in Pregnancy Study (CHIPS): what is the optimal strategy to manage hypertension during pregnancy? Hypertension. 2016;68:36-38. doi: 10.1161/HYPERTENSIONAHA. 116.07190.
91. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010. Art No CD000025.
92. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet. 2002;359:1877-1890. doi: 10.1016/S0140-6736(02)08778-0.
93. Ludmir J, Vigil-De Gracia P. Is magnesium sulfate use of benefit post partum? A randomized controlled trial. Am J Obstet Gynecol. 2017;216(suppl 1):S3-S4.
94. Brown MA, Gallery ED. Volume homeostasis in normal pregnancy and pre-eclampsia: physiology and clinical implications. Baillieres Clin Obstet Gynaecol. 1994;8:287-310.
95. Dennis AT, Castro JM. Hypertension and haemodynamics in pregnant women-is a unified theory for pre-eclampsia possible? Anaesthesia. 2014;69:1183-1189. doi: 10.1111/anae.12832.
96. Melchiorre K, Sutherland G, Sharma R, Nanni M, Thilaganathan B. Mid-gestational maternal cardiovascular profile in preterm and term pre-eclampsia: A prospective study. BJOG. 2013;120:496-504. doi: 10.1111/1471-0528.12068.
97. August P, Malha L. Postpartum hypertension: "it ain't over 'til it's over". Circulation. 2015;132:1690-1692. doi: 10.1161/CIRCULATIONAHA. 115.019510.
98. Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol. 2004;190:577-578. doi: 10.1016/j.ajog.2003.08.030.
99. Viteri OA, England JA, Lash KA, Villegas MI, Ashimi Balogun OA, Chauhan SP, Sibai BM. Should non-steroidal anti-inflammatory drugs be avoided in puerperal hypertensive women? Am J Obstet Gynecol. 2017;216(suppl 1):S34-S35.
100. Wasden SW, Ragsdale ES, Chasen ST, Skupski DW. Impact of non-steroidal anti-inflammatory drugs on hypertensive disorders of pregnancy. Pregnancy Hypertens. 2015;4:259-263.
101. Porcel J, Feigal C, Poye L, Postma IR, Zeeman GG, Olowoyeye A, Tsigas E, Wilson M. Hypertensive disorders of pregnancy and risk of screening positive for posttraumatic stress disorder: A cross-sectional study. Pregnancy Hypertens. 2013;3:254-260. doi: 10.1016/j.preghy.2013.07.004.
102. Theilen L, Meeks H, Fraser A, Esplin MS, Smith KR, Varner M. Longterm mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol. 2017;216(suppl 1): S32-S33.
103. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Horvath J, Hennessy A. Hypertension in pregnancy and long-term cardiovascular mortality: A retrospective cohort study. Am J Obstet Gynecol. 2016;214:722.e1-722. e6. doi: 10.1016/j.ajog.2015.12.047.
104. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974. doi: 10.1136/bmj.39335. 385301.BE.
105. van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015;212:624.e1-624.17. doi: 10.1016/j.ajog. 2015.01.009.
106. Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J, Mangos G, Davis G. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG. 2007;114:984-993. doi: 10.1111/j. 1471-0528.2007.01376.x.
107. Breetveld NM, Ghossein-Doha C, van Kuijk S, van Dijk AP, van der Vlugt MJ, Heidema WM, Scholten RR, Spaanderman ME. Cardiovascular disease risk is only elevated in hypertensive, formerly preeclamptic women. BJOG. 2015;122:1092-1100. doi: 10.1111/1471-0528.13057.
108. Spaan J, Peeters L, Spaanderman M, Brown M. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension. 2012;60:1368-1373. doi: 10.1161/HYPERTENSIONAHA.112.198812.
109. Mangos GJ, Spaan JJ, Pirabhahar S, Brown MA. Markers of cardiovascular disease risk after hypertension in pregnancy. J Hypertens. 2012;30:351-358. doi: 10.1097/HJH.0b013e32834e5ac7.
110. Davis GK, Roberts L, Mangos G, Henry A, Pettit F, O'Sullivan A, Homer CS, Craig M, Harvey SB, Brown MA. Postpartum physiology, psychology and paediatric follow up study (P4 Study): study protocol. Pregnancy Hypertens. 2016;6:374-379. doi: 10.1016/j.preghy. 2016.08.241.
111. van der Merwe JL, Hall DR, Harvey J. Does a patient information sheet lead to better understanding of pre-eclampsia? A randomised controlled trial. Pregnancy Hypertens. 2011;1:225-230. doi: 10.1016/j.preghy.2011.06.001.
112. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, Paech MJ, Said JM; Society of Obstetric Medicine of Australia and New Zealand. The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55:11-16 doi: 10.1111/ajo.12253.
113. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:416-441. doi: 10.1016/S1701-2163(15)30588-0.
114. ACOG. Hypertension in pregnancy: executive summary. Obstet Gynecol. 2013;122:1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.
115. World Health Organization (WHO). Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. 2011. http://www.who.int/reproductivehealth/ publications/maternal-perinatal-health/9789241548335/ en/.
116. World Health Organization, UNICEF, United Nations Population Fund. Managing Complications in Pregnancy and Childbirth: A Guide for Midwives and Doctors. 2nd ed. Integrated Management of Pregnancy and Childbirth. 2017. http://www.who.int/maternal-child-adolescent/ documents/managing-complications-pregnancy-childbirth/en/.